05:44 PM EDT, 03/20/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said late Wednesday the European Commission approved Abecma to treat adult patients with relapsed and refractory multiple myeloma who have received at least two previous therapies.

The approval covers patients who have shown disease progression on the last therapy, the company said.

Abecma has maintained its orphan designation to treat multiple myeloma in the EU, Bristol Myers said, adding that the expanded approval covers all EU member states.

Price: 51.9, Change: +0.02, Percent Change: +0.04